A meta‐analysis comparing first‐line immunosuppressants in neuromyelitis optica-Reference-Cited by-同舟云学术

A meta‐analysis comparing first‐line immunosuppressants in neuromyelitis optica

Published:2021-09-10 Issue:10 Volume:8 Page:2025-2037
ISSN:2328-9503
Container-title:Annals of Clinical and Translational Neurology
language:en
Short-container-title:Ann Clin Transl Neurol

Author:

Giovannelli Jonathan¹,Ciron Jonathan²,Cohen Mikael³,Kim Ho‐Jin⁴,Kim Su‐Hyun⁴,Stellmann Jan‐Patrik⁵,Kleiter Ingo⁶⁷,McCreary Morgan⁸,Greenberg Benjamin M.⁸,Deschamps Romain⁹,Audoin Bertrand¹⁰^ORCID,Maillart Elisabeth¹¹¹²,Papeix Caroline¹¹¹²,Collongues Nicolas¹³,Bourre Bertrand¹⁴,Laplaud David¹⁵,Ayrignac Xavier¹⁶^ORCID,Durand‐Dubief Françoise¹⁷,Ruet Aurélie¹⁸,Vukusic Sandra¹⁷,Marignier Romain¹⁷¹⁹^ORCID,Dauchet Luc²⁰,Zephir Hélène²¹^ORCID,

Affiliation:

1. GIOVANNELLI Epidemiology and Clinical Research Counselling Lille France

2. Department of Neurology CRC‐SEP Hôpital Purpan CHU de Toulouse Toulouse France

3. CRCRSEP Nice UR2CA URRIS Université Nice Côte d’Azur Neurologie CHU Pasteur 2 Nice France

4. Department of Neurology Research Institute & Hospital of National Cancer Center Goyang Korea

5. Aix‐Marseille University CNRS CRMBM UMR 7339 APHM Hôpital de la Timone CEMEREM Marseille 13005 France

6. Department of Neurology St. Josef Hospital Ruhr University Bochum Bochum Germany

7. Marianne‐Strauß‐Klinik Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke Berg Germany

8. Department of Neurology University of Texas Southwestern Dallas TexasUSA

9. Department of Neurology Hôpital Fondation Adolphe de Rothschild Paris France

10. Aix‐Marseille Université Service de Neurologie Pôle de Neurosciences Cliniques APHM, Hôpital de la Timone Marseille France

11. Department of Neurology Hôpital Pitié Salpêtrière AP‐HP Paris France

12. National Referral Center of Rare Inflammatory Brain and Spinal Diseases (MIRCEM) Paris France

13. Biopathologie de la Myéline Neuroprotection et Stratégies Thérapeutiques U1119 Fédération de Médecine Translationnelle de Strasbourg Strasbourg France

14. Department of Neurology CHU de Rouen Rouen France

15. Université de Nantes CHU Nantes Inserm Centre de Recherche en Transplantation et Immunologie UMR 1064 Nantes F‐44000 France

16. Department of Neurology CHU Montpellier INM University of Montpellier Inserm Montpellier France

17. Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon Lyon France

18. University of Bordeaux Inserm U1215 – Neurocentre Magendie CHU de Bordeaux Neurologie et Maladies inflammatoires du système nerveux central Bordeaux F‐33000 France

19. Service de Neurologie Sclérose en Plaques Pathologies de la Myéline et Neuroinflammation Centre de Référence des maladies Inflammatoires Rares du Cerveau et de la Moelle U1028 CNRS UMR 5292 Center for Research in Neuroscience of Lyon Lyon 1 University Lyon France

20. University of Lille INSERM, CHU Lille Institut Pasteur de Lille U1167‐RID‐AGE‐Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement Lille F‐59000 France

21. Department of Neurology CRCSEP Lille CHU de Lille University of Lille Inserm U1172 Lille France

Publisher

Wiley

Subject

Neurology (clinical),General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acn3.51451

Reference36 articles.

1. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

2. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury

3. The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica

4. Connexins in neuromyelitis optica: a link between astrocytopathy and demyelination

5. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM);Multiple Sclerosis and Related Disorders;2024-09

2. Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations;Revue Neurologique;2024-07

3. New treatment options for Neuromyelitis optica spectrum disorders (NMOSD);Neurologie pro praxi;2024-06-20

4. Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease;Magnetic Resonance Imaging Clinics of North America;2024-05

5. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder;Multiple Sclerosis and Related Disorders;2024-05